4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(4-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)pyrimidin-2-amine | 1182185-95-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-(6-(morpholin-4-yl)pyridin-3-yl)-N-(4-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl)pyrimidin-2-amine
• 英文别名: N-[4-(8-methyl-3,8-diazabicyclo[3.2.1]octan-3-yl)phenyl]-4-(6-morpholin-4-ylpyridin-3-yl)pyrimidin-2-amine
• CAS: 1182185-95-0
• 化学式: C₂₆H₃₁N₇O
• 分子量: 457.578
• InChiKey: MMAAFGGZCPZNED-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  8

文献信息

• PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
  申请人：Bhamidipati Somasekhar

  公开号：US20090258864A1

  公开（公告）日：2009-10-15

  This invention is directed to compounds of formula (I): where n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising the compounds of formula (I); and methods of using the compounds and the pharmaceutical compositions in treating diseases or conditions associated with JAK2 activity.

  本发明涉及式(I)的化合物：其中，n、m、Y、R1、R2、R3、R4和R5在此被披露，作为分离的立体异构体或其混合物，或其药学上可接受的盐；包括式(I)化合物的制药组合物；以及使用该化合物和制药组合物治疗与JAK2活性相关的疾病或病症的方法。
• US8309566B2
  申请人：——

  公开号：US8309566B2

  公开（公告）日：2012-11-13
• US8735418B2
  申请人：——

  公开号：US8735418B2

  公开（公告）日：2014-05-27
• US9624229B2
  申请人：——

  公开号：US9624229B2

  公开（公告）日：2017-04-18
• [EN] A COMBINATION FOR IMMUNE MEDIATED CANCER TREATMENT<br/>[FR] COMBINAISON À MÉDIATION IMMUNITAIRE POUR LE TRAITEMENT DU CANCER
  申请人：RIGEL PHARMACEUTICALS INC

  公开号：WO2017007658A1

  公开（公告）日：2017-01-12

  Disclosed embodiments concern a combination comprising a JAK inhibitor and an immunooncology agent. The immunooncology agent may comprise an anti-PD- 1 antibody, anti- PD-L1 antibody, PI3K inhibitor, indole dioxygenase inhibitor or a combination thereof. The JAK inhibitor may be a pyrimidin-2-amine, 2,4-pyrimidinediamine, or a combination thereof. Also disclosed are embodiments of a method for using the combination to treat a subject, particularly a subject having a cell proliferative disorder. The method may further comprise administering one or more therapeutic agents in addition to the JAK inhibitor and immunooncology agent. Kits comprising the combination are also disclosed.